Ļć½¶ŹÓʵ

Anna Chalmers
( out of 56 reviews )

Anna Chalmers, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Salt Lake City
801-585-0100

Sugar House Health Center

Salt Lake City
801-581-2000

  • Anna Chalmers, M.D. is an Assistant Professor in Division of Oncology and an investigator at the Huntsman Cancer Institute. Dr. Chalmers is a specialist in adult medical oncology, with a focus in sarcoma. She joined the faculty in 2016 and see patients at the Huntsman Cancer Institute in Salt Lake City and Sugarhouse.

    Dr. Chalmers received her bachelorā€™s degree from Dartmouth College and her medical degree from Drexel Ļć½¶ŹÓʵ College of Medicine. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at Rush Ļć½¶ŹÓʵ Medical Center in Chicago.

    Dr. Chalmers is actively involved in research. She is committed to utilizing clinical studies to benefit her patients at the Huntsman Cancer Institute. She is a member of several international organizations, including the Connective Tissue Oncology Society and the American Society of Clinical Oncology.

    Dr. Chalmers is a native of Newport Beach, California. She enjoys hiking, sailing, and skiing with her children and husband, who is an orthopedic surgeon at the Ļć½¶ŹÓʵ of Utah.

    Specialties

    Board Certification

    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Patient Rating

    4.9 /5
    ( out of 56 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    September 28, 2024
    HUNTSMAN CANCER CENTER

    Very positive and caring. I could tell she was very knowledgeable. Made me feel comfortable Told me of the treatment to follow

    September 13, 2024
    HUNTSMAN CANCER CENTER

    She was very kind, and showed me that she was willing to help me anyway she could

    September 12, 2024
    HUNTSMAN CANCER CENTER

    With 8 years of experience with Dr. Chalmers I highly recommend her. My medical attention was always great. My cancer is a great concern but with the confident medical treatment I am doing well.

    July 31, 2024
    HUNTSMAN CANCER CENTER

    Dr. Chalmers has been with me for over 8 years of fighting these rare tumors. She is always caring and knowledgable.

    July 30, 2024
    HUNTSMAN CANCER CENTER

    Always kind and caring - excellent care provider.

    July 18, 2024
    HUNTSMAN CANCER CENTER

    SHE A SUPER PERSON AND SUPER DOCTOR

    July 17, 2024
    HUNTSMAN CANCER CENTER

    I have been coming to Huntsman for 10 years for treatments, have seen many very good Dr.'s. But without a doubt, Dr. Chalmers is one of the BEST! She treats me not only as her patient first, but also cares about me a person!

    June 04, 2024
    HUNTSMAN CANCER CENTER

    If you need a cancer doctor, Doctor Chalmers is peerless!

    April 10, 2024
    HUNTSMAN CANCER CENTER

    Es una experiencia muy buena ya que ella es una Doctora muy profesional en su trabajo siempre preocupada y viendo lo mejor para mi como pasiente.muchas gracias.

    See More Patient Comments

  • Anna Chalmers, M.D. is an Assistant Professor in Division of Oncology and an investigator at the Huntsman Cancer Institute. Dr. Chalmers is a specialist in adult medical oncology, with a focus in sarcoma. She joined the faculty in 2016 and see patients at the Huntsman Cancer Institute in Salt Lake City and Sugarhouse.

    Dr. Chalmers received her bachelorā€™s degree from Dartmouth College and her medical degree from Drexel Ļć½¶ŹÓʵ College of Medicine. She completed her residency in Internal Medicine and fellowship in Hematology and Medical Oncology at Rush Ļć½¶ŹÓʵ Medical Center in Chicago.

    Dr. Chalmers is actively involved in research. She is committed to utilizing clinical studies to benefit her patients at the Huntsman Cancer Institute. She is a member of several international organizations, including the Connective Tissue Oncology Society and the American Society of Clinical Oncology.

    Dr. Chalmers is a native of Newport Beach, California. She enjoys hiking, sailing, and skiing with her children and husband, who is an orthopedic surgeon at the Ļć½¶ŹÓʵ of Utah.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Primary
    Academic Divisions Oncology
    Board Certification
    American Board of Internal Medicine
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)

    Education history

    Fellowship Hematology and Medical Oncology - Rush Ļć½¶ŹÓʵ Medical Center Fellow
    Internal Medicine - Rush Ļć½¶ŹÓʵ Medical Center Resident
    Professional Medical Medicine - Drexel Ļć½¶ŹÓʵ College of Medicine M.D.
    Dartmouth College B.A.

    Selected Publications

    Journal Article

    1. Puri S, Malani R, Chalmers A, Kerrigan K, Patel SB, Monynahan K, Cannon L, Blouw B, Akerley W (2023). Keeping a track on leptomeningeal disease in non-small cell lung cancer: A single-institution experience with CNSide(TM). Neurooncol Adv, 6(1), vdad150. ()
    2. Kerrigan K, Patel SB, Haaland B, Ose D, Weinberg Chalmers A, Haydell T, Meropol NJ, Akerley W (2020). Prognostic Significance of Patient-Reported Outcomes in Cancer. JCO Oncol Pract, 16(4), e313-e323. ()
    3. Chalmers AW, Patel S, Boucher K, Cannon L, Esplin M, Luckart J, Graves N, Van Duren T, Akerley W (2019). Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up. Target Oncol, 14(4), 417-421. ()
    4. Chalmers A, Cannon L, Akerley W (2018). Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib. Oncologist, 24(7), 963-972. ()

    Editorial

    1. Chalmers AW, Patel SB, Akerley W (2018). Immunotherapy after chemoradiotherapy in stage III non-small cell lung cancer: a new standard of care? J Thorac Dis, 10(3), 1198-1200. ()

    Letter

    1. Chalmers A, Akerley W (2017). Retrospective, Multi-Institutional Analysis of Sequential Treatment of Brain Metastases in Treatment-NaĆÆve, Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer Should Not Define the Standard of Practice. [Letter to the editor]. J Clin Oncol, 35(20), 2340. ()

  • News & Podcasts

    Huntsman Cancer Institute News